Outlook Therapeutics, Inc. (OTLK) 2020年年度报告「NASDAQ」.pdf

《Outlook Therapeutics, Inc. (OTLK) 2020年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Outlook Therapeutics, Inc. (OTLK) 2020年年度报告「NASDAQ」.pdf（132页珍藏版）》请在三个皮匠报告上搜索。

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended September 30,2020ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、 OF 1934For the transition period from to Commission File Number:001-37759OUTLOOK THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware 38-3982704(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)4260 U.S.Route 1Monmouth Juncti

3、on,New Jersey08852(Address of principal executive offices)(Zip Code)(609)619-3990(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Trading Symbol(s)Name of each exchange on which registeredCommon StockOTLKThe Nasdaq Stock

4、Market LLCSeries A WarrantsOTLKWThe Nasdaq Stock Market LLCSecurities Registered Pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not requir

5、ed to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorterperiod than the regist

6、rant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of thi